Science News
from research organizations

Among antidementia drugs, memantine is associated with the highest risk of pneumonia

Date:
November 21, 2016
Source:
University of Eastern Finland
Summary:
Among users of antidementia drugs, persons using memantine have the highest risk of pneumonia, new research shows. The use of rivastigmine patches is associated with an increased risk as well, say researchers.
Share:
FULL STORY

A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of rivastigmine patches is associated with an increased risk as well.

The study found that persons using donepezil or galantamine had the lowest risk of pneumonia. However, persons using memantine or rivastigmine patches had a 1.6 and 1.15 times higher risk of pneumonia, respectively, but no elevated risk was observed among patients using rivastigmine in capsule form. The real risk increase may be even higher, as only cases of pneumonia leading to hospitalisation or death were taken into account.

The study is the first to compare the risk of pneumonia associated with different antidementia drugs and drug forms. The results are not likely to be explained by differences between drug molecules, as rivastigmine was associated with an increased risk of pneumonia in patch form only. The increased pneumonia risk among persons using memantine or rivastigmine patches may be explained at least partly by the fact that these medications are often used in more advanced states of dementia. However, all participants were home-dwelling persons.

The study is based on data from a nationwide register-based study (MEDALZ) conducted at the University of Eastern Finland. The risk of pneumonia was compared among users of different antidementia drugs. The study population consisted of 65,481 persons diagnosed with Alzheimer's disease during 2005-2011 in Finland.

No cure for Alzheimer's diseases currently exists, but the progression of the disease can be slowed down by antidementia drugs, such as memantine and acetylcholinesterase inhibitors such as donepezil, galantamine, and rivastigmine. Persons with Alzheimer's disease have an elevated risk of pneumonia, and it is one of the most common causes of hospitalisation among persons with Alzheimer's disease. Pneumonia is also a common cause of death in this population.

The findings published in the Annals of Medicine.


Story Source:

Materials provided by University of Eastern Finland. Note: Content may be edited for style and length.


Journal Reference:

  1. Pasi Lampela, Anna-Maija Tolppanen, Antti Tanskanen, Jari Tiihonen, Piia Lavikainen, Sirpa Hartikainen, Heidi Taipale. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease. Annals of Medicine, 2016; 1 DOI: 10.1080/07853890.2016.1254349

Cite This Page:

University of Eastern Finland. "Among antidementia drugs, memantine is associated with the highest risk of pneumonia." ScienceDaily. ScienceDaily, 21 November 2016. <www.sciencedaily.com/releases/2016/11/161121093500.htm>.
University of Eastern Finland. (2016, November 21). Among antidementia drugs, memantine is associated with the highest risk of pneumonia. ScienceDaily. Retrieved May 24, 2017 from www.sciencedaily.com/releases/2016/11/161121093500.htm
University of Eastern Finland. "Among antidementia drugs, memantine is associated with the highest risk of pneumonia." ScienceDaily. www.sciencedaily.com/releases/2016/11/161121093500.htm (accessed May 24, 2017).

RELATED STORIES